Showing session: reset
Precision Medicine Early Clinical Trials
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
- Free
- slides video
- audio + slides
- All slides included
Discussant
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE"
Patrick Schoffski
University Hospitals Leuven - Department of General Medical Oncology, Leuven, Belgium
- Free
- slides video
- audio + slides
- All slides included
Discussant
Ravi Salgia
City of Hope, Duarte, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S Hong
MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA, United States